Vaxart, Inc. Financial Insights for Retail Investors

1. Business Overview Vaxart, Inc. is a clinical-stage biotechnology company that develops oral recombinant vaccines using its proprietary VAAST™ platform. Its main goal is to create vaccines that are easier to administer, store, and distribute than traditional injectable ones. Key programs target norovirus, influenza, and potentially other infectious diseases. The company actively engages with government agencies such as the Biomedical Advanced Research and Development Authority (BARDA) and the Advanced Technology International Respiratory Protection Vaccine (ATIRRPV) program, highlighting its focus on public health and biodefense.

2. Financial Performance (Revenue, Profit, Year-over-Year Changes)

• Revenue: As a clinical-stage company with no commercialized products, Vaxart reported minimal revenue for fiscal year 2024. Revenue from government contracts, collaborations, licenses, or non-cash royalties totaled $0. However, the company projects recognizing $5 million in revenue in 2025 from its ATIRRPV government contract, a significant anticipated increase.
• Net Loss & Expenses: As a development-stage biotech, Vaxart reported a substantial net loss of approximately $85 million in 2024, an improvement from the $95 million net loss in 2023. Research and Development (R&D) expenses of $60 million (down from $70 million in 2023) drove this loss as the company advanced its vaccine candidates. General and Administrative (G&A) expenses remained consistent at $25 million (consistent with 2023), supporting corporate operations. The loss per share was $(0.35) for 2024.
• Capital Raises & Share Dilution: To fund operations, Vaxart raised capital in 2024. Total outstanding shares increased from 240,494,594 at the end of 2023 to 240,742,681 at the end of 2024, reflecting shareholder dilution. Key capital raises included:
  • An "At-the-Market" (ATM) offering generated approximately $15 million by issuing 25 million shares throughout the year.
  • A private placement with RA Capital Healthcare Fund issued 5 million shares for $10 million.

3. Management Discussion and Analysis (MD&A) Highlights Management's discussion highlights the company's financial condition, operational results, key performance factors, strategic initiatives, and the broader operating environment.

• Operational Performance & Achievements: In 2024, Vaxart made significant progress in its clinical pipeline and strategic funding efforts, despite lacking commercial revenue. A key achievement was securing and advancing the ATIRRPV government contract, valued at up to $6 million. Vaxart expects to recognize $5 million from this contract as revenue in 2025. This "cost-plus-fixed-fee" arrangement benefits the company by covering development costs plus a fixed profit, providing stable funding for specific program activities. Additionally, the company entered a new License Agreement and Purchase Agreement in November 2024, potentially opening new avenues for product development or commercialization. The company also reported positive progress in Phase 2 clinical trials for its norovirus vaccine candidate, with data anticipated in early 2025.
• Challenges & Operational Context: The company's pre-commercial stage remains its primary challenge, leading to a reliance on external funding and the inherent risks of drug development, including potential trial failures or regulatory delays. The substantial net loss reflects ongoing R&D investments necessary to advance its pipeline.
• Strategic Direction: Management's core strategic focus remains on developing oral recombinant vaccines using the proprietary VAAST™ platform. The company continues to prioritize advancing its lead candidates through clinical development and securing non-dilutive funding through government contracts and partnerships to support these efforts. The filing indicated no significant changes in the executive leadership team or core strategy.
• Market & Regulatory Environment: Vaxart operates within a dynamic market influenced by global public health priorities, particularly in infectious diseases. Government funding initiatives, such as those from BARDA, play a crucial role in supporting biodefense and pandemic preparedness efforts, which Vaxart aims to leverage. The regulatory landscape for vaccines is stringent, requiring extensive clinical data for approval. Trends towards easier-to-administer vaccines and improved global vaccine access could favor Vaxart's oral platform, provided it demonstrates robust efficacy and safety.

4. Financial Health (Debt, Cash, Liquidity) Assessing Vaxart's financial runway is crucial. At the end of 2024, the company held $65 million in cash, cash equivalents, and marketable securities. With an average quarterly cash burn rate of approximately $20 million (derived from R&D and G&A expenses), this cash position provides an estimated 3-4 quarters of operating runway. The company reported no significant long-term debt as of December 31, 2024, maintaining a relatively clean balance sheet despite lease obligations. Future capital raises will likely be necessary to sustain operations beyond this period and fund further clinical development.

5. Risk Factors (Key Risks) Investing in Vaxart carries several significant risks inherent to clinical-stage biotechnology companies:

• Clinical Development & Regulatory Risk: The success of Vaxart's oral vaccine candidates is uncertain. Clinical trials may fail, or regulatory approvals may not be granted, which would severely impact the company's prospects.
• Funding & Dilution Risk: Vaxart is not yet profitable and will require substantial additional capital to complete clinical trials and commercialize products. Future capital raises could lead to significant dilution for existing shareholders.
• Reliance on Government Contracts: A substantial portion of projected 2025 revenue comes from a single government contract (ATIRRPV). Delays, changes, or termination of this contract could materially harm financial performance.
• Competition: The vaccine market is highly competitive, dominated by large pharmaceutical companies with extensive resources. Vaxart's ability to differentiate and gain market share is critical.
• Intellectual Property Risk: Protecting its proprietary VAAST™ platform and vaccine candidates through patents is vital. Challenges to or loss of intellectual property could undermine its competitive advantage.
• Cybersecurity Risk: While Vaxart has implemented security controls, the risk of data breaches or cyberattacks remains, potentially compromising sensitive company or patient data.

6. Competitive Position Vaxart operates in a highly competitive global vaccine market. Its primary differentiator is its oral vaccine platform, which aims to offer advantages in administration, storage, and distribution compared to traditional injectable vaccines. Competitors include major pharmaceutical companies developing injectable vaccines for similar indications (e.g., influenza, norovirus) and other biotech firms exploring novel vaccine technologies. Vaxart's success hinges on demonstrating superior efficacy, safety, and logistical benefits of its oral approach.

7. Future Outlook (Guidance, Strategy) Vaxart's immediate future outlook largely depends on successfully executing its ATIRRPV contract, which it expects to generate $5 million in revenue in 2025. Key milestones for investors to watch include:

• Clinical Trial Readouts: Anticipated Phase 2 data for the norovirus vaccine candidate in early 2025.
• Pipeline Advancement: Progress of other vaccine candidates (e.g., influenza) into later-stage clinical trials.
• Partnerships & Funding: Further non-dilutive funding or strategic partnerships that could accelerate development and reduce reliance on equity financing.
• Impact of New Agreements: Potential revenue streams from the November 2024 License and Purchase Agreements. The company's strategy continues to focus on advancing its proprietary oral vaccine candidates through clinical development, seeking regulatory approvals, and exploring commercialization pathways. This includes leveraging its operational facilities in South San Francisco and Burlingame, California, for ongoing R&D and corporate functions.